(BIOA) BioAge Labs - Overview
Stock: Azelaprag, BGE-102, Obesity, Neuroinflammation, NLRP3
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 81.0% |
| Relative Tail Risk | -11.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.34 |
| Alpha | 337.59 |
| Character TTM | |
|---|---|
| Beta | 0.608 |
| Beta Downside | 0.165 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.23% |
| CAGR/Max DD | 0.10 |
Description: BIOA BioAge Labs December 25, 2025
BioAge Labs, Inc. (NASDAQ:BIOA) is a U.S.-based biopharmaceutical firm focused on developing therapeutics for metabolic diseases by leveraging a proprietary platform that integrates human aging datasets to pinpoint molecular targets linked to age-related decline.
The company’s lead asset, azelaprag, is an oral small-molecule currently in a Phase 1 trial for obesity and has entered a Phase 2 study in combination with tirzepatide targeting older adults-a demographic with rising obesity prevalence. A second program, BGE-102, is a brain-penetrant NLRP3 antagonist aimed at neuroinflammatory conditions, reflecting BioAge’s broader ambition to address age-driven pathologies.
As of the latest filing (Q3 2024), BioAge reported a market capitalization of roughly $210 million, cash and equivalents of $85 million, and a runway of about 12 months at current burn rates. The global obesity treatment market is estimated at >$200 billion and is expanding at ~8% CAGR, while the neuroinflammation space is attracting heightened R&D spending, suggesting a favorable macro backdrop but also intense competition from established players such as Novo Nordisk and Eli Lilly.
For a deeper, data-driven view of BIOA’s valuation and risk profile, consider checking ValueRay’s analyst tools.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -75.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.19 > 0.02 and ΔFCF/TA -3.02 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.19 > 3% & CFO -58.5m > Net Income -75.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (35.9m) vs 12m ago 925.9% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.84% > 50% (prev 0.0%; Δ 1.84% > 0%) |
| Interest Coverage Ratio: -81.02 > 6 (EBITDA TTM -74.7m / Interest Expense TTM 924.0k) |
Altman Z'' -10.80
| A: 0.87 (Total Current Assets 290.8m - Total Current Liabilities 24.5m) / Total Assets 305.1m |
| B: -1.01 (Retained Earnings -307.5m / Total Assets 305.1m) |
| C: -0.23 (EBIT TTM -74.9m / Avg Total Assets 321.2m) |
| D: -11.12 (Book Value of Equity -307.2m / Total Liabilities 27.6m) |
| Altman-Z'' Score: -10.80 = D |
What is the price of BIOA shares?
Over the past week, the price has changed by +2.04%, over one month by +46.19%, over three months by +173.83% and over the past year by +364.03%.
Is BIOA a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the BIOA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.7 | -23.6% |
| Analysts Target Price | 15.7 | -23.6% |
| ValueRay Target Price | 22.4 | 9% |
BIOA Fundamental Data Overview February 07, 2026
P/S = 140.986
P/B = 3.0337
Revenue TTM = 5.92m USD
EBIT TTM = -74.9m USD
EBITDA TTM = -74.7m USD
Long Term Debt = 2.50m USD (from longTermDebt, last fiscal year)
Short Term Debt = 4.71m USD (from shortTermDebt, last quarter)
Debt = 7.13m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -208.4m USD (from netDebt column, last quarter)
Enterprise Value = 555.6m USD (834.2m + Debt 7.13m - CCE 285.8m)
Interest Coverage Ratio = -81.02 (Ebit TTM -74.9m / Interest Expense TTM 924.0k)
EV/FCF = -9.39x (Enterprise Value 555.6m / FCF TTM -59.1m)
FCF Yield = -10.65% (FCF TTM -59.1m / Enterprise Value 555.6m)
FCF Margin = -999.6% (FCF TTM -59.1m / Revenue TTM 5.92m)
Net Margin = -1281 % (Net Income TTM -75.8m / Revenue TTM 5.92m)
Gross Margin = unknown ((Revenue TTM 5.92m - Cost of Revenue TTM 58.0k) / Revenue TTM)
Tobins Q-Ratio = 1.82 (Enterprise Value 555.6m / Total Assets 305.1m)
Interest Expense / Debt = 2.09% (Interest Expense 149.0k / Debt 7.13m)
Taxrate = 21.0% (US default 21%)
NOPAT = -59.1m (EBIT -74.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.87 (Total Current Assets 290.8m / Total Current Liabilities 24.5m)
Debt / Equity = 0.03 (Debt 7.13m / totalStockholderEquity, last quarter 277.5m)
Debt / EBITDA = 2.79 (negative EBITDA) (Net Debt -208.4m / EBITDA -74.7m)
Debt / FCF = 3.52 (negative FCF - burning cash) (Net Debt -208.4m / FCF TTM -59.1m)
Total Stockholder Equity = 302.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.59% (Net Income -75.8m / Total Assets 305.1m)
RoE = -25.09% (Net Income TTM -75.8m / Total Stockholder Equity 302.1m)
RoCE = -24.58% (EBIT -74.9m / Capital Employed (Equity 302.1m + L.T.Debt 2.50m))
RoIC = -19.17% (negative operating profit) (NOPAT -59.1m / Invested Capital 308.5m)
WACC = 8.09% (E(834.2m)/V(841.3m) * Re(8.15%) + D(7.13m)/V(841.3m) * Rd(2.09%) * (1-Tc(0.21)))
Discount Rate = 8.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 119.1%
Fair Price DCF = unknown (Cash Flow -59.1m)
EPS Correlation: 56.29 | EPS CAGR: 6.39% | SUE: 0.0 | # QB: 0
Revenue Correlation: 77.91 | Revenue CAGR: 146.3% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.66 | Chg30d=-0.015 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-2.67 | Chg30d=+0.111 | Revisions Net=+0 | Growth EPS=-21.3% | Growth Revenue=-58.0%